Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ADXS's Cash-to-Debt is ranked higher than
88% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. ADXS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ADXS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 3.53 Max: No Debt
Current: No Debt
Equity-to-Asset 0.67
ADXS's Equity-to-Asset is ranked higher than
51% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ADXS: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
ADXS' s Equity-to-Asset Range Over the Past 10 Years
Min: -10.71  Med: 0.17 Max: 0.93
Current: 0.67
-10.71
0.93
Interest Coverage No Debt
ADXS's Interest Coverage is ranked higher than
84% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ADXS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ADXS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -2.69
Beneish M-Score: 43.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -678.23
ADXS's Operating Margin % is ranked lower than
71% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. ADXS: -678.23 )
Ranked among companies with meaningful Operating Margin % only.
ADXS' s Operating Margin % Range Over the Past 10 Years
Min: -16623.33  Med: -2471.43 Max: -678.23
Current: -678.23
-16623.33
-678.23
Net Margin % -655.66
ADXS's Net Margin % is ranked lower than
71% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. ADXS: -655.66 )
Ranked among companies with meaningful Net Margin % only.
ADXS' s Net Margin % Range Over the Past 10 Years
Min: -8206.06  Med: -1746.85 Max: 3096.67
Current: -655.66
-8206.06
3096.67
ROE % -96.41
ADXS's ROE % is ranked lower than
75% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. ADXS: -96.41 )
Ranked among companies with meaningful ROE % only.
ADXS' s ROE % Range Over the Past 10 Years
Min: -874.87  Med: -200.72 Max: -62.63
Current: -96.41
-874.87
-62.63
ROA % -69.49
ADXS's ROA % is ranked lower than
75% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ADXS: -69.49 )
Ranked among companies with meaningful ROA % only.
ADXS' s ROA % Range Over the Past 10 Years
Min: -386.9  Med: -108.13 Max: 45.93
Current: -69.49
-386.9
45.93
ROC (Joel Greenblatt) % -1793.41
ADXS's ROC (Joel Greenblatt) % is ranked lower than
69% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. ADXS: -1793.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ADXS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -27114.29  Med: -8478.66 Max: 1183.45
Current: -1793.41
-27114.29
1183.45
3-Year EBITDA Growth Rate -18.10
ADXS's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ADXS: -18.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ADXS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.2  Med: -17.4 Max: 41.1
Current: -18.1
-30.2
41.1
3-Year EPS without NRI Growth Rate -20.20
ADXS's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. ADXS: -20.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ADXS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.1  Med: -13.7 Max: 11.9
Current: -20.2
-42.1
11.9
GuruFocus has detected 4 Warning Signs with Advaxis Inc ADXS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ADXS's 30-Y Financials

Financials (Next Earnings Date: 2017-10-31)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ADXS Guru Trades in Q3 2016

Paul Tudor Jones 26,596 sh (New)
Jim Simons Sold Out
» More
Q4 2016

ADXS Guru Trades in Q4 2016

Paul Tudor Jones Sold Out
» More
Q1 2017

ADXS Guru Trades in Q1 2017

Paul Tudor Jones 34,700 sh (New)
» More
Q2 2017

ADXS Guru Trades in Q2 2017

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ADXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2834
Compare:NAS:VSTM, XKRX:019175, XKRX:053030, NAS:AVXL, LSE:BVXP, ROCO:6617, LSE:SLN, NAS:ALRN, NAS:OCUL, NAS:ALBO, LSE:TRX, XTER:PA8, TSX:FRX, NAS:VCEL, NAS:SBPH, ASX:BNO, OSTO:MVIR B, ROCO:6567, TPE:1720, TPE:1701 » details
Traded in other countries:FAD1.Germany,
Headquarter Location:USA
Advaxis Inc focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies.

Advaxis Inc is a clinical stage biotechnology company operating in the United States. It focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology which utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate Specific Antigen (PSA) associated with prostate cancer.

Top Ranked Articles about Advaxis Inc

Insiders Roundup: Twitter, McKesson Make Biggest Trades Largest insider trades of the Week
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “Sept. 2017” and All Insider Sales to “$5,000,000+." Read more...
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Advaxis, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis' Clinical Trials
Advaxis Appoints Anthony Lombardo as Chief Business Officer
Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac

PRINCETON, N.J., March 27, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today published online a poster previously presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool that showed axalimogene filolisbac achieved durable response in a patient with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC).
Nine patients who had documented disease progression after they had received curative treatments of chemotherapy and/or radiation with or without bevacizumab were enrolled in this phase 1, open-label, dose-determining study.  Axalimogene filolisbac was well-tolerated across two dose levels.  The study also established a recommended phase 2 dose of 1×1010 CFU and demonstrated antitumor activity at that dose. Axalimogene filolisbac was safely administered at 5 and 10 times the dose levels previously studied, without any significant toxicity. One patient experienced an ongoing and durable partial response.  This patient was recently featured in the Augusta Chronicle, as she is being treated at the Georgia Cancer Center at Augusta University.  Read the full Augusta Chronicle article here. “The best overall tumor response in eight of the nine enrolled patients is encouraging in evaluating the potential of axalimogene filolisbac,” said Sharad Ghamande, principal investigator and Professor and Director of Gynecologic Oncology at the Georgia Cancer Center at Augusta University.  “We were pleased to see a sustained and durable partial response in one patient, which is very rare for this kind of tumor that is unresponsive to chemotherapy, and survival in these patients is often less than 10 months. In addition, we could safely administer the drug at 5 and 10 times the dose levels previously studied, without any significant toxicity.” There was only one instance of dose-limiting toxicity, with that patient experiencing a grade 3 treatment related adverse event (TRAE) of hypotension at a dose of 5×109 CFU.  Across all doses, eight of nine patients experienced a grade 1-2 TRAE, including chills, nausea and hypotension. The poster on the phase 1 data, “High-dose treatment with ADXS11-001, a Listeria monocytogenes-listeriolysin O (Lm-LLO) immunotherapy, in women with cervical cancer: a phase I, dose-escalation study” (no. 58) is available at www.advaxis.com.  The company is preparing to initiate a phase 3 trial in PRmCC later this year. About Axalimogene Filolisbac Axalimogene filolisbac is a targeted Listeria monocytogenes (Lm)-based immunotherapy that attacks HPV-associated cancers by altering a live strain of Lm bacteria to generate cancer-fighting T cells against cancer antigens while neutralizing the tumor’s natural protections that guard the tumor microenvironment from immunologic attack.  In a phase 2 trial evaluating axalimogene filolisbac for the treatment of persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC), the drug candidate showed a 12-month overall survival rate of 38 percent observed in 50 patients in the trial.  This is a 52 percent improvement over the 12-month overall survival rate that was expected in the trial’s patient population based on prognostic factors. Axalimogene filolisbac has received Fast Track designation for adjuvant therapy for high-risk locally advanced cervical cancer (HRLACC) and a Special Protocol Assessment for the Phase 3 AIM2CERV trial in HRLACC patients.  The immunotherapy has also received orphan drug designation in three clinical indications. About Advaxis, Inc. Located in Princeton, N.J., Advaxis, Inc. is a biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology immunotherapy, axalimogene filolisbac, targets HPV-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a SPA for the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA’s CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, an investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to commence a Phase 1 clinical trial in 2017. To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube. Advaxis Forward-Looking Statement This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapy, axalimogene filolisbac. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements. CONTACTS: Company: Advaxis, Inc.
Ranya Dajani, Vice President, Business Development
[email protected]
609.250.7559 Media Contact: JPA Health Communications
David Connolly
[email protected]
617.945.9316


Read more...
EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer

PRINCETON, N.J., March 23, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced the European Medicines Agency (EMA) issued an advanced therapy medicinal product certificate for manufacturing quality and non-clinical data.  The certification procedure involved a thorough scientific evaluation over several months of the quality (CMC) data and non-clinical data by the EMA’s Committee for Advanced Therapies (CAT).  After a positive opinion from CAT, EMA issued a certificate confirming that the CMC and non-clinical data comply with the standards that apply for evaluating the Marketing Authorization Application (MAA) of axalimogene filolisbac for the treatment of metastatic cervical cancer.  Advaxis is now positioned to file the complete MAA in the second half of 2017.
“EMA’s issuance of this certification is a major milestone for Advaxis,” said Daniel J. O’Connor, President and CEO.  “With a significant portion of the MAA now reviewed and certified, we are preparing to file the complete MAA as we work to bring this innovative immunotherapy to patients with metastatic cervical cancer who have limited treatment options.” About Axalimogene Filolisbac Axalimogene filolisbac is a targeted Listeria monocytogenes (Lm)-based immunotherapy that attacks HPV-associated cancers by altering a live strain of Lm bacteria to generate cancer-fighting T cells against cancer antigens while neutralizing the tumor’s natural protections that guard the tumor microenvironment from immunologic attack.  In a phase 2 trial evaluating axalimogene filolisbac for the treatment of persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC), the drug candidate showed a 12-month overall survival rate of 38 percent observed in 50 patients in the trial.  This is a 52 percent improvement over the 12-month overall survival rate that was expected in the trial’s patient population based on prognostic factors. Axalimogene filolisbac has received Fast Track designation for adjuvant therapy for high-risk locally advanced cervical cancer (HRLACC) and a Special Protocol Assessment for the Phase 3 AIM2CERV trial in HRLACC patients.  The immunotherapy has also received orphan drug designation in three clinical indications. About Advaxis, Inc. Located in Princeton, N.J., Advaxis, Inc. is a biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology immunotherapy, axalimogene filolisbac, targets HPV-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a SPA for the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA’s CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, an investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to commence a Phase 1 clinical trial in 2017. To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube. Advaxis Forward-Looking Statement This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapy, axalimogene filolisbac. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements. CONTACTS: Company: Advaxis, Inc.
Ranya Dajani, Vice President, Business Development
[email protected]
609.250.7559 Media Contact: JPA Health Communications
David Connolly
[email protected] 
617.945.9316


Read more...
Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer

- Achieved primary objective of 12-month survival rate, demonstrating axalimogene filolisbac is an active therapy in metastatic cervical cancer
- Unprecedented 12-month survival rate for metastatic cervical cancer observed PRINCETON, N.J., March 15, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, presented data from the GOG-0265 study at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer in National Harbor, MD.  GOG-0265 is a single arm, Phase 2 trial evaluating axalimogene filolisbac for the treatment of persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC).  The primary endpoints of the study were to assess the safety and efficacy of axalimogene filolisbac in women with PRmCC.  The primary efficacy endpoint was overall survival at 12 months from initial treatment with axalimogene filolisbac. The primary safety endpoints were to evaluate the number of patients with dose-limiting toxicities and the frequency and severity of adverse effects. The final efficacy results of GOG-0265 demonstrated that 38% of patients (n = 19/50) with heavily pretreated PRmCC were alive 12 months following treatment with axalimogene filolisbac.  The GOG-0265 study protocol used a logistic model-based calculation to establish the expected 12-month survival rate.  The model identified the key prognostic factors of age, race and performance status significantly related to survival from a database of approximately 500 patients with PRmCC who participated in 17 previous phase 2 studies conducted by the Gynecologic Oncology Group (GOG), now part of NRG Oncology.  Using this model, the expected 12-month survival rate of patients enrolled in the study was calculated to be 24.5%.  As a result, the 38% 12-month survival rate of patients treated with axalimogene filolisbac represents a 52% improvement over the expected survival rate and is the highest 12-month survival rate achieved to date in this setting.  The probability of this survival improvement being detected by chance versus a true treatment effect was calculated to be 0.02.  A compelling and ongoing complete response of 18.5 months was observed and the longest ongoing survival is 40.6 months. “The 12-month survival rate of axalimogene filolisbac reached unprecedented levels in this study, which is both impressive and important given the lack of innovation in metastatic cervical cancer,” said Warner K. Huh, MD, Division Director of Gynecologic Oncology at the University of Alabama at Birmingham, and Lead Investigator of the study. The safety profile was consistent with previous clinical experience.  The most common Grade 1 or Grade 2 treatment-related adverse events (TRAEs) were hypotension and symptoms related to cytokine release (e.g., nausea, chills, fever).  Eighteen out of 50 patients experienced a Grade 3 TRAE and two out of 50 patients experienced a Grade 4 TRAE, which were hypotension and symptoms related to cytokine release.  The abstract was selected by SGO for prominence as an oral late-breaking presentation by Charles A. Leath III, M.D., MSPH, Associate Professor of Obstetrics and Gynecology at the University of Alabama at Birmingham School of Medicine, entitled, “A prospective phase 2 trial of the listeria-based HPV immunotherapy axalimogene filolisbac in second and third-line metastatic cervical cancer: A NRG Oncology Group trial,” on March 14 at 2:30 p.m. ET. Slides from the presentation are available at www.advaxis.com/sgo2017.

Highlights from Dr. Leath’s presentation include: A 38% (n = 19/50) 12-month survival rate in second- and third-line PRmCC treated with axalimogene filolisbac, representing a 52% improvement over the expected 12-month milestone survival rate of 24.5%Eight patients remain alive as of January 31, 2017 (Range 12.02 – 40.6 months)Disease control (complete response, partial response, or stable disease) was achieved in 32% of patients based on investigator assessment of best responseA durable complete response in a patient with PRmCC previously treated with chemotherapy and bevacizumab remains ongoing at 18.5 monthsResults compare favorably to GOG Study 227C of bevacizumab, which demonstrated a 12-month milestone overall survival (OS) rate of 30% in a similar patient population which subsequently supported regulatory approval in first-line treatment in combination with chemotherapy in 2014Consistent with its immunotherapy mechanism of action, axalimogene filolisbac demonstrated a promising plateau in the survival curve, indicating potential long-term clinical benefit for a subset of patients with PRmCCAxalimogene filolisbac was generally well-tolerated, with primarily infusion-associated, low grade, transient TRAEs (≥30%), such as fatigue, chills, anemia, nausea and feverOnly 2 patients experienced grade 4 TRAEs Advaxis plans to initiate a global, phase 3 randomized registration study in patients with metastatic cervical cancer later this year. About the Phase 2 GOG-0265 Study GOG-0265 is an open-label, single arm 2-stage study designed to evaluate the safety, tolerability and efficacy of axalimogene filolisbac  to treat PRmCC as conducted by the Gynecologic Oncology Group (GOG), now part of NRG Oncology.  Patients who progressed on or after at least 1 prior line of systemic-dose chemotherapy receive one cycle (three doses) of axalimogene filolisbac at 1 x 109 CFU every 28 days.  The primary efficacy endpoint was the 12-month survival rate, with secondary efficacy objective to evaluate progression-free survival, overall survival and objective tumor response.  The primary safety endpoints were to evaluate the number of patients with dose-limiting toxicities and the frequency and severity of adverse effects. The expected 12-month overall survival rate (null hypothesis) was established using a prospectively-defined logistic model-based calculation derived from 17 serially conducted GOG/NRG 2-stage studies in PRmCC involving approximately 500 patients, adjusting for prognostic factors (age, performance status, race) significantly related to survival.  In accordance with the prior trials, GOG/NRG used a consistent protocol design/data collection methodology for the current 2-stage GOG-0265 study in PRmCC, which contributed to a robust and homogeneous patient dataset for the primary endpoint analysis.   About Cervical Cancer Cervical cancer is the fourth most common cancer in women worldwide.  An estimated 13,000 new cases will be diagnosed in the United States in 2016, and 4,100 people will die of the disease, according to the National Cancer Institute.  Persistent HPV infection is the most important factor in the development of cervical cancer, research shows.  According to the ICO Information Centre on HPV and Cervical Cancer, about 4.4% of women in the United States are estimated to harbor high-risk cervical HPV infection at a given time, and about 72% of cervical cancers are attributed to high-risk HPV strains.  PRmCC is a fatal disease, and the prognosis for women with advanced and recurrent cervical cancer remains poor, with survival of only 4 to 7 months following failure of first-line treatment, research has shown.  There is no therapy following failure of first-line treatment.  According to the American Cancer Society, the five-year mortality rate for metastatic disease is at just 17%, with the area continuing to be a high unmet medical need. About the GOG Foundation, Inc. The GOG Foundation, Inc. (GOG) is a non-profit international organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies.  The GOG is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results.  Continuous evaluation of its processes is utilized in order to constantly improve the quality of patient care.  The GOG conducts clinical trials for patients with a variety of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina and vulva.  General information on many of these trials for medical professionals and the lay public can be obtained from ClinicalTrials.gov. NRG Oncology is one of four adult US Network groups funded under the newly structured NCI National Clinical Trials Network.  NRG Oncology is comprised of three legacy cooperative groups, the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). About Advaxis, Inc. Located in Princeton, N.J., Advaxis, Inc. is a biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™.  The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth.  Advaxis' lead Lm Technology immunotherapy, axalimogene filolisbac, targets HPV-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer.  The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for high risk locally advanced cervical cancer (HRLACC) patients and a SPA for the Phase 3 AIM2CERV trial in HRLACC patients.  Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA’s CAT.  Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development.  In addition, Advaxis and Amgen are developing ADXS-NEO, a preclinical investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to enter the clinic in 2017. For additional information on Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube. Advaxis Forward-Looking Statement This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapy, axalimogene filolisbac.  These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation.  We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements. CONTACTS: Company: Advaxis, Inc.
Ranya Dajani, Vice President, Business Development
[email protected]
609.250.7515 Media Contact: JPA Health Communications
David Connolly
[email protected]
617.945.9316


Read more...
Advaxis to Present at the 2017 Barclays Global Healthcare Conference

PRINCETON, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced that Sara Bonstein, Chief Financial Officer of Advaxis, will present a corporate overview at the 2017 Barclays Global Healthcare Conference being held in Miami on March 14-16.
Event: 2017 Barclays Global Healthcare Conference
Presentation Date: March 14, 2017
Presentation Time: 8:30 a.m. ET
Location: Loews Miami Beach Hotel, Miami Beach, FL About Advaxis, Inc. Located in Princeton, N.J., Advaxis, Inc. is a biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology immunotherapy, axalimogene filolisbac, targets HPV-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for high risk locally advanced cervical cancer (HRLACC) patients and a SPA for the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA’s CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, a preclinical investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to enter the clinic in 2017. To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube. Advaxis Forward-Looking Statement This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapy, axalimogene filolisbac. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements. CONTACTS: Company: Advaxis, Inc.
Ranya Dajani, Vice President, Business Development
[email protected]
609.250.7559 Media Contact: JPA Health Communications
David Connolly
[email protected] 
617.945.9316


Read more...
Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical

PRINCETON, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced Al Blunt, M.D., has joined the company as Vice President of Medical. Dr. Blunt joins Advaxis from Covance, a leading global clinical research organization and drug development service company, where he was Executive Medical Director for Oncology.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/96307afe-58e4-46f6-9fcf-849d3c61f4bb. Dr. Blunt joined Covance in 1998, holding several positions increasing in responsibility over nearly 20 years. He was responsible for medical monitoring for ongoing oncology trials across all phases, frequently interacting with staff at clinical trial sites, and providing oncology subject matter expertise company-wide. He also led Covance’s immuno-oncology curriculum and global training. “As both a clinical oncologist and drug developer, Al brings tremendous insight and experience from years of planning, leading and executing clinical trials that have led to successful approvals and commercial launches,” said Chris Duke, Chief Operating Officer of Advaxis. As Vice President of Medical for Advaxis, Dr. Blunt is responsible for leading the company’s clinical development strategy and activities from pre-clinical to commercial phase trials, including development of trial protocols to preparing regulatory filings, and participating in interactions with regulatory authorities relating to clinical matters. “Advaxis’ versatile and complementary technology and drug candidates have great potential to provide an immuno-therapeutic approach to patients who currently have limited options for treating cervical cancer, anal cancer and many other cancers,” said Dr. Blunt. “I look forward to working with the company’s leadership and hundreds of clinicians throughout the world who are working to bring these much-needed therapies to patients.” Dr. Blunt holds a medical degree from the University of Pennsylvania School of Medicine and a B.S. in biochemistry from the City College of the City University of New York. He completed his residency at the Children’s Hospital of Philadelphia and his fellowship in pediatric hematology-oncology at the Washington University School of Medicine and St. Louis Children’s Hospital. He received an American Cancer Society Clinical Fellowship and a Howard Hughes Medical Institute Postdoctoral Fellowship for Physicians Award. Dr. Blunt’s appointment was effective March 7. As part of his compensation, he receives 54,500 restricted stock units in Advaxis, of which 25 percent vest immediately and the remaining shares vest annually over the next three years. About Advaxis, Inc. Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology immunotherapy, axalimogene filolisbac, targets HPV-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for high risk locally advanced cervical cancer (HRLACC) patients and a Special Protocol Assessment for the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA’s CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, a preclinical investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to enter the clinic in 2017. For additional information on Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube. Advaxis Forward-Looking Statement This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapy, axalimogene filolisbac. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements. CONTACTS: Company: Advaxis, Inc.
Ranya Dajani, Vice President, Business Development
[email protected]
609.250.7559 Media Contact: JPA Health Communications
David Connolly
[email protected] 
617.945.9316


Read more...
Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO

PRINCETON, N.J., March 06, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has indicated the Investigational New Drug (IND) application for ADXS-NEO, a personalized neoantigen-targeted approach to cancer immunotherapy that is being developed in collaboration with Amgen, can proceed.
This ground-breaking IND paves the way for bringing a new precision immunotherapy for the treatment of cancers into the clinic this year. ADXS-NEO employs Advaxis’ proprietary Listeria monocytogenes (Lm)-based antigen delivery technology, its Lm Technology™, to target multiple patient-specific neoantigens in each individual patient’s tumor that are not present in normal cells. ADXS-NEO is designed to stimulate both the innate and adaptive arms of the immune system. Advaxis bioengineers ADXS-NEO constructs by programming its Lm-based antigen delivery technology to present the unique protein fragments or neoantigens associated with mutations found in a patient’s own cancer cells. These cancer-specific mutations are identified by comparing the DNA sequences of cancer cells with normal cells. ADXS-NEO works by presenting a large payload of neoantigens directly into dendritic cells within the patient’s immune system to generate new cancer-fighting white blood cells. These T cells hunt down cancer cells bearing these neoantigens while at the same time broadly stimulating the immune system and reducing the ability of the cancer to resist. ADXS-NEO constructs can present multiple neoantigens that can be targeted by a patient’s immune system simultaneously. Tumors may accumulate up to 100 or more mutations that can generate neoantigens, and each patient has a set of mutations that are unique to his or her own tumors. ADXS-NEO is designed to hit multiple targets at once to improve the likelihood of a benefit. ADXS-NEO will be manufactured in Advaxis’ newly constructed facility in Princeton, N.J., utilizing a process that minimizes the time required to develop the patient-specific immunotherapy. A single manufacturing run can provide sufficient product to treat each patient repeatedly for more than one year. “The IND acceptance is a landmark step towards escaping the one-size-fits-all approach to cancer treatments by building innovative, patient-specific immunotherapies. This highly personalized approach has the potential to transform the treatment of care across multiple types of cancers,” said Robert Petit, Ph.D., Chief Scientific Officer of Advaxis. “This enables us to employ Lm Technology to focus the attention of a patient’s immune system against the very mutations within their cancer that turned their cells malignant in the first place.” ADXS-NEO is under development through a collaboration between Amgen and Advaxis, bringing together Amgen’s expertise in immuno-oncology development and commercialization and Advaxis’ proprietary Lm-based antigen delivery technology and it’s My Immunotherapy Neo-Epitopes or MINE™ platform. Advaxis plans to initiate a phase 1 trial evaluating ADXS-NEO in multiple tumor types later this year. “Over the past several years, the field of cancer immunotherapy has brought promising new treatments with meaningful benefits to cancer patients. Amgen remains committed to a multi-modality approach in immunotherapy, and our collaboration with Advaxis adds to the toolkit of cancer-fighting options available for patients,” said David M. Reese, Senior Vice President, Translational Sciences at Amgen. “We look forward to our continued work with Advaxis to explore the potential of ADXS-NEO in the clinic and across multiple tumor types.” About Advaxis, Inc. Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology. The Lm Technology, using bioengineered live attenuated Lm bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology immunotherapy, axalimogene filolisbac, targets HPV-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for high risk locally advanced cervical cancer (HRLACC) patients and a SPA for the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA’s CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, a preclinical investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to enter the clinic in 2017. To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube. Advaxis Forward-Looking Statement This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapy, axalimogene filolisbac. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements. CONTACTS: Company: Advaxis, Inc.
Ranya Dajani, Vice President, Business Development
[email protected]
609.250.7559 Media Contact: JPA Health Communications
David Connolly
[email protected] 
617.945.9316 


Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.07
ADXS's PB Ratio is ranked higher than
73% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ADXS: 2.07 )
Ranked among companies with meaningful PB Ratio only.
ADXS' s PB Ratio Range Over the Past 10 Years
Min: 1.78  Med: 3.51 Max: 26.44
Current: 2.07
1.78
26.44
PS Ratio 10.82
ADXS's PS Ratio is ranked lower than
51% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. ADXS: 10.82 )
Ranked among companies with meaningful PS Ratio only.
ADXS' s PS Ratio Range Over the Past 10 Years
Min: 10.82  Med: 75 Max: 2037.14
Current: 10.82
10.82
2037.14
EV-to-EBIT -0.72
ADXS's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. ADXS: -0.72 )
Ranked among companies with meaningful EV-to-EBIT only.
ADXS' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.4  Med: -3.5 Max: 25.8
Current: -0.72
-28.4
25.8
EV-to-EBITDA -0.72
ADXS's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. ADXS: -0.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
ADXS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.6  Med: -3.7 Max: 22.8
Current: -0.72
-30.6
22.8
EV-to-Revenue 4.71
ADXS's EV-to-Revenue is ranked higher than
69% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. ADXS: 4.71 )
Ranked among companies with meaningful EV-to-Revenue only.
ADXS' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.6  Med: 94.5 Max: 1645.9
Current: 4.71
5.6
1645.9
Current Ratio 4.60
ADXS's Current Ratio is ranked higher than
54% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ADXS: 4.60 )
Ranked among companies with meaningful Current Ratio only.
ADXS' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.55 Max: 29.36
Current: 4.6
0.01
29.36
Quick Ratio 4.60
ADXS's Quick Ratio is ranked higher than
56% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. ADXS: 4.60 )
Ranked among companies with meaningful Quick Ratio only.
ADXS' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.55 Max: 29.36
Current: 4.6
0.01
29.36
Days Sales Outstanding 44.98
ADXS's Days Sales Outstanding is ranked higher than
67% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. ADXS: 44.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
ADXS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.98  Med: 240.29 Max: 631.82
Current: 44.98
44.98
631.82

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -42.90
ADXS's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ADXS: -42.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ADXS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -119.8  Med: -47.6 Max: -32
Current: -42.9
-119.8
-32

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.94
ADXS's Price-to-Net-Cash is ranked higher than
80% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. ADXS: 2.94 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ADXS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.14  Med: 4.58 Max: 375
Current: 2.94
2.14
375
Price-to-Net-Current-Asset-Value 2.53
ADXS's Price-to-Net-Current-Asset-Value is ranked higher than
83% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. ADXS: 2.53 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ADXS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.11  Med: 4.04 Max: 93.75
Current: 2.53
2.11
93.75
Price-to-Tangible-Book 2.24
ADXS's Price-to-Tangible-Book is ranked higher than
77% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. ADXS: 2.24 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ADXS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.09  Med: 3.71 Max: 56.48
Current: 2.24
2.09
56.48
Price-to-Median-PS-Value 0.14
ADXS's Price-to-Median-PS-Value is ranked higher than
95% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ADXS: 0.14 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ADXS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 0.94 Max: 15.74
Current: 0.14
0.14
15.74
Earnings Yield (Greenblatt) % -142.72
ADXS's Earnings Yield (Greenblatt) % is ranked lower than
93% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. ADXS: -142.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ADXS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -239.4  Med: -27.1 Max: 5
Current: -142.72
-239.4
5

More Statistics

Revenue (TTM) (Mil) $14.01
EPS (TTM) $ -2.30
Beta1.72
Short Percentage of Float28.92%
52-Week Range $3.76 - 10.88
Shares Outstanding (Mil)41.07

Analyst Estimate

Oct17 Oct18 Oct19 Oct20
Revenue (Mil $) 13 12 11 35
EPS ($) -2.13 -2.10 -2.16 -2.00
EPS without NRI ($) -2.13 -2.10 -2.16 -2.00
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}